Natural Polysaccharide-Based Nanodrug Delivery Systems for Treatment of Diabetes.

In recent years, natural polysaccharides have been considered as the ideal candidates for novel drug delivery systems because of their good biocompatibility, biodegradation, low immunogenicity, renewable source and easy modification. These natural polymers are widely used in the designing of nanocarriers, which possess wide applications in therapeutics, diagnostics, delivery and protection of bioactive compounds or drugs. A great deal of studies could be focused on developing polysaccharide nanoparticles and promoting their application in various fields, especially in biomedicine. In this review, a variety of polysaccharide-based nanocarriers were introduced, including nanoliposomes, nanoparticles, nanomicelles, nanoemulsions and nanohydrogels, focusing on the latest research progress of these nanocarriers in the treatment of diabetes and the possible strategies for further study of polysaccharide nanocarriers.

Direct fibrogenic effects of dispersed single-walled carbon nanotubes on human lung fibroblasts.

Nanomaterials, including single-walled carbon nanotubes (SWCNT), are being developed for a variety of commercial products. However, adverse health effects attributed to these new materials are not well understood. Recent reports showed that exposure of mice to dispersed SWCNT (DSWCNT) produced a rapid and progressive interstitial lung fibrosis without persistent inflammation. To understand the mechanism underlying this unusual fibrogenicity of DSWCNT, the present investigation focused on the direct bioactivity of DSWCNT using a cell culture of lung fibroblasts that represent a major cell type resident in the lung interstitium and responsible for the production of collagen matrix. At concentrations relevant to those used in vivo, in vitro exposure of lung fibroblasts to DSWCNT stimulated cell proliferation and induced collagen production without producing cell damage. One of the major matrix metalloproteinases (MMP), MMP-9, which is known to be involved in lung fibrosis, was also elevated by DSWCNT treatment both in vitro and in vivo. Taken together, these results suggest that direct stimulation of fibroblasts by DSWCNT translocated into the interstitium may play a significant role in DSWCNT-induced lung fibrosis. Our data also suggest that the dispersion status and/or size of the SWCNT structures is a critical factor in determining nanoparticle fibrogenicity and that MMP-9 may be involved in the fibrogenic process. The results obtained may aid in the development of in vitro models for rapid screening of the potential fibrogenicity of carbon nanotubes, which are lacking and urgently needed.

Sedation With Propofol Has No Effect on Capsule Endoscopy Completion Rates: A Prospective Single-Center Study.

Patients who need both capsule endoscopy (CE) and colonoscopy often undergo both examinations on the same day to avoid repeated bowel preparation and fasting. Sedation can relieve pain and is commonly used for colonoscopies but may influence the CE completion rate.To determine whether sedation with propofol influences the completion rate and small-bowel transit time (SBTT) of CE.From July 2014 to December 2014, patients (18-65 years old) who needed both CE and colonoscopy were assessed consecutively for enrollment in our study. Colonoscopies were performed with or without sedation based on patient preferences on the day of capsule ingestion. The completion rate, SBTT, and diagnostic yield of CEs were recorded. Patients' satisfaction and pain scores were also recorded.Sedation with propofol had no significant effect on CE completion rates (83.3% sedation group vs 81.8% nonsedation group, P = 0.86) but was associated with increased SBTT (403.6 ±â€Š160.3 sedation group vs 334.5 ±â€Š134.4 nonsedation group, P = 0.006). The diagnostic yields in the sedation and nonsedation groups were 69.4% and 65.9%, respectively (P = 0.74). The median satisfaction scores were 8.6 in the sedation group and 3.5 in the nonsedation group (P < 0.001). Median pain scores were 1.4 in the sedation group and 6.7 in the nonsedation group (P < 0.001).Sedation with propofol increased SBTT but had no effect on CE completion rates, suggesting that CE and colonoscopy with propofol can be performed on the same day (clinical trial registration number: ChiCTR-ONRC-14004866).